MAGL-IN-1 manufacturers
- MAGL-IN-1
-
- $34.00
-
2026-05-11
- CAS:2324160-91-8
- Purity:
- Supply Ability: 10g
|
| | MAGL-IN-1 Basic information |
| Product Name: | MAGL-IN-1 | | Synonyms: | MAGL-IN-1;MAGLIN1,MAGL IN 1;(1-(2-fluoro-5-hydroxybenzoyl)piperidin-4-yl)(4-isopropylphenyl)methanone | | CAS: | 2324160-91-8 | | MF: | C22H24FNO3 | | MW: | 369.43 | | EINECS: | | | Product Categories: | | | Mol File: | 2324160-91-8.mol |  |
| | MAGL-IN-1 Chemical Properties |
| Boiling point | 558.9±50.0 °C(Predicted) | | density | 1.214±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 25 mg/ml; DMF:PBS (pH 7.2) (1:6): 0.14 mg/ml; DMSO: 20 mg/ml; Ethanol: 2.5 mg/ml | | form | A crystalline solid | | pka | 9.51±0.18(Predicted) | | color | White to off-white |
| | MAGL-IN-1 Usage And Synthesis |
| Description | MAGL inhibitor compound 23 is an inhibitor of monoacylglycerol lipase (MAGL; IC50 = 80 nM).1 It is selective for MAGL over cannabinoid receptor 1 (CB1), CB2, fatty acid amide hydrolase (FAAH), α/β-hydrolase domain-containing protein 6 (ABHD6), and ABHD12 (IC50s = >10 μM). MAGL inhibitor compound 23 inhibits the growth of HCT116, MDA-MB-231, Caov-3, OVCAR-3, and SKOV3 cells (IC50s = 21, 7.9, 25, 57, and 15 μM, respectively) but not MRC5 cells (IC50 = >100 μM). It increases the levels of 2-arachidonoyl glycerol (2-AG; ) in mouse brain and plasma when administered at a dose of 50 mg/kg. | | Uses | MAGL-IN-1 is a potent, selective, reversible and competitive inhibitor of MAGL, with an IC50 of 80 nM. MAGL-IN-1 exhibits anti-proliferative effects against human breast, colorectal, and ovarian cancer cells. MAGL-IN-1 blocks MAGL in cell-based as well as in vivo assays[1]. | | in vivo | MAGL (compound 23) (50 mg/kg; a single i.p.) increases the 2-AG level in plasma and brain, and does not alter anandamide (AEA), arachidonic acid and prostaglandin levels in plasma and brain of mice[1]. | Animal Model: | Male C57BL6 mice, 8-10 weeks old[1] | | Dosage: | 50 mg/kg | | Administration: | Intraperitoneal injection; once | | Result: | Increased 2-AG levels in the brain and plasma. |
| | References | 1. Granchi, C., Lapillo, M., Glasmacher, S., et al. Optimization of a benzoylpiperidine class identifies a highly potent and selective reversible monoacylglycerol lipase (MAGL) inhibitor J. Med. Chem. 62(4),1932-1958(2019). |
| | MAGL-IN-1 Preparation Products And Raw materials |
|